Wire · opportunities
FDA clears blood test to aid evaluation for Alzheimer's disease
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 21 August 2026 · Fusion42 review
The FDA cleared PrecivityAD2, a blood test developed by WashU Medicine and C2N Diagnostics, to aid Alzheimer's diagnosis by detecting amyloid plaque biomarkers with over 90% accuracy. This test offers a less invasive alternative to spinal taps and brain scans and supports earlier treatment initiation.
This Wire brief sits within Fusion42's coverage of Digital Health, and 13 sources have reported it between 20 Aug 2026 and 26 Sep 2026.
◆ ◆ The Wire takeaway
You now have FDA-backed access to a less invasive Alzheimer’s diagnostic tool that can speed patient diagnosis and treatment uptake. Healthtech founders should engage insurers and clinicians to scale adoption before competitors enter.
◆ Coverage
13 sources · first reported 20 Aug 2026 · latest 26 Sep 2026
◆ Related on Wire
◆ Topics